101 
Market Cap
As of July 16, 2010: $28,822,000.00
Stock Chart
Avexa - 30 Day Poll
Recent BLOGS About Avexa Add New
 |
Avexa - buy or sell now that it has given up on it…
Given AVX is down almost 80% does anyone feel it should be a buy or sell now that it has given up on… Read more
|
Latest Company News
|
Avexa Limited Licenses One Of Its HIV Integrase Programs To Chinese Partner
Reuters Key Development - Jul 13, 2010 |
|
AUSTRALIAN DRUG FIRM AVEXA APPOINTS INTERIM CEO
Trading Markets - Jul 13, 2010 Australian drug development company Avexa Ltd (ASX:AVX) has appointed drug inventor Dr Jonathan Coates as its new interim chief executive officer. Dr Coates will serve as CEO while the company ...
|
|
Avexa Limited Appoints Dr. Jonathan Coates As Chief Scientific Officer And Interim Chief Executive Officer
Reuters Key Development - Jul 12, 2010 |
|
Avexa up by a third this month
CFO World - Jul 5, 2010 By CFO World Staff (CFO World) Shares in Avexa Limited (ASX:AVX) have risen by over a third since the beginning of July. The drug discovery and development company recently announced that it was ...
|
|
Avexa Closes Apricitabine (Atc) Program
PharmaLive.com - May 10, 2010 Melbourne, Australia, 10 May 2010. The Board of Avexa Limited (ASX:AVX) has resolved to cease any further development of its lead HIV program, ATC, following the unsuccessful conclusion of ...
Avexa shares drop 78%, HIV program axed - Business SpectatorAvexa: Last Potential Partner Bails, ATC Drug Effort Nixed - BioWorld Online |
Website
Videos related to Avexa
Company Profile
Cash Assets: approx. $28M as of 30th Mar 2010. For 2008 & 2009 the company has had a loss of approxiamtely $18M each year.
Avexa is engaged in the development and commercialization of anti-infective pharmaceutical programs and projects. Avexa's principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by:
- Human Immunodeficiency Virus (HIV)
- Vancomycin- and methicillin-resistant bacteria.
Avexa is engaged in the development and commercialization of anti-infective pharmaceutical programs and projects. Avexa's principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by:
- Human Immunodeficiency Virus (HIV)
- Vancomycin- and methicillin-resistant bacteria.
Its lead program is apricitabine (ATC), which is in phase III trials. Apricitabine is nucleoside reverse transcriptase inhibitors (NRTI) for the treatment of human immunodeficiency virus (HIV) infection. The phase III study is conducted in 130 specialist HIV centers in 15 countries. This drug is targetd at 2nd, 3rd and 4th line therapy for cases of drug resiatnce to other treatment modalities.
The company’s other HIV focus, an integrase program, focuses to identify compounds, which inhibit HIV integrase, the enzyme for inserting the viral genome into the host cell deoxyribonucleic acid (DNA).
Its antibacterial program is focused on identifying compounds with antibacterial activity against antibiotic-resistant micro-organisms. A lead molecule, AVX13616, is selected for pre-clinical testing.
Possible Upcoming events:
Apricitabine (ATC) is in a phase III study.
Related companies or competition:
- Gilead Sciences
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use